Cerulean Pharma Inc. To Present At Biocentury's Newsmakers In Biotechnology Conference
CAMBRIDGE, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq:CERU), a leader in Dynamic Tumor Targeting™, today announced that Oliver S. Fetzer, Ph.D., President and Chief Executive Officer, will present BioCentury's 2014 Newsmakers in the Biotech Industry Conference on Friday, September 26th at 1:30 p.m. ET in New York.
A live audio webcast of the presentation will be available on the "Investors" section of the Company's website, www.ceruleanrx.com with the replay available for two weeks following the presentation.
About Cerulean Pharma
The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com.
CONTACT: For IR: Heather Savelle MacDougall Biomedical Communications 781.235.3060 hsavelle@macbiocom.com For PR: Laura Kempke MSLGROUP 781.684.0770 cerulean@mslgroup.com 